FOLH1 and neoplasm: A new, intriguing option for improving [177Lu]Lu-PSMA RLT in patients naïve to the radiopharmaceuticals might be the combination with the immune checkpoint inhibitor pembrolizumab with its potential for synergistically remodeling the tumor microenvironment.